Dr. Steven Albelda earned his medical degree from the Perelman School of Medicine at University of Pennsylvania (Penn), where he also completed his internal medicine residency and additional training in research. He is board-certified in critical care medicine, internal medicine, and pulmonary medicine.
Dr. Albelda currently holds multiple positions at Penn, including Professor of Medicine, Associate Director of the Pulmonary Division, Director of the Thoracic Oncology Research Laboratory, and Co-Director of the Translational Center of Excellence for Lung Cancer. Some of his special areas of interest include the asbestos-related cancers of mesothelioma and lung cancer.
Dr. Steven Albelda’s translational research focuses on molecular biology and immunogene therapy for thoracic malignancies such as lung cancer and mesothelioma.
Dr. Albelda’s translational research focuses on molecular biology and immunogene therapy for thoracic malignancies such as lung cancer and mesothelioma. He studies the tumor microenvironment, anti-tumor immune effects, T-cell dysfunction, and T-cell transfer. Dr. Albelda is also involved in immunogene clinical trials. His research is funded by the National Cancer Institute.
Dr. Albelda has compiled the findings of his research into over 140 peer-reviewed journal articles. He has also contributed to scholarly work in his field by serving on multiple editorial boards, including as Associate Editor for the American Journal of Respiratory Cell and Molecular Biology. He continues to work tirelessly to advance lung cancer and mesothelioma research.